Brookfield Asset Management Ltd. (BAM)vsBlackRock Technology and Private Equity Term Trust (BTX)
BAM
Brookfield Asset Management Ltd.
$44.90
-4.39%
FINANCIAL SERVICES · Cap: $76.95B
BTX
BlackRock Technology and Private Equity Term Trust
$8.73
-4.89%
FINANCIAL SERVICES · Cap: $1.07B
Smart Verdict
WallStSmart Research — data-driven comparison
BAM leads profitability with a 49.7% profit margin vs 0.0%. BTX trades at a lower P/E of 24.8x. BAM earns a higher WallStSmart Score of 68/100 (B-).
BAM
Strong Buy68
out of 100
Grade: B-
BTX
Avoid26
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 33 in profit
Keeps 50 of every $100 in revenue as profit
Strong operational efficiency at 64.5%
Large-cap with strong market position
Revenue surging 23.8% year-over-year
No standout strengths identified
Areas to Watch
Premium valuation, high expectations priced in
Trading at 9.5x book value
Grey zone — moderate risk
Weak financial health signals
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : BAM
The strongest argument for BAM centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 49.7% and operating margin at 64.5%. Revenue growth of 23.8% demonstrates continued momentum.
Bull Case : BTX
BTX has a balanced fundamental profile.
Bear Case : BAM
The primary concerns for BAM are P/E Ratio, Price/Book, Altman Z-Score.
Bear Case : BTX
The primary concerns for BTX are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
BAM profiles as a growth stock while BTX is a value play — different risk/reward profiles.
BAM is growing revenue faster at 23.8% — sustainability is the question.
BTX generates stronger free cash flow (878M), providing more financial flexibility.
Monitor ASSET MANAGEMENT industry trends, competitive dynamics, and regulatory changes.
Bottom Line
BAM scores higher overall (68/100 vs 26/100), backed by strong 49.7% margins and 23.8% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Brookfield Asset Management Ltd.
FINANCIAL SERVICES · ASSET MANAGEMENT · USA
Brookfield Asset Management is a leading global alternative asset manager and one of the largest investors in real assets.
Visit Website →BlackRock Technology and Private Equity Term Trust
FINANCIAL SERVICES · ASSET MANAGEMENT · USA
Brooklyn ImmunoTherapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to developing therapies to treat cancer patients. The company is headquartered in Brooklyn, New York.
Visit Website →Compare with Other ASSET MANAGEMENT Stocks
Want to dig deeper into these stocks?